Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1. 1.

   Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

   Recruiting — Phase 1 — Merck Sharp & Dohme LLC

   https://clinicaltrials.gov/study/NCT02861573

2. 2.

   Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

   Recruiting — Phase 3 — Celcuity Inc

   https://clinicaltrials.gov/study/NCT06757634

3. 3.

   Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

   Recruiting — Phase 3 — UMC Utrecht

   https://clinicaltrials.gov/study/NCT02735707

4. 4.

   A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   Recruiting — Phase 3 — Children's Oncology Group

   https://clinicaltrials.gov/study/NCT04293562

5. 5.

   Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

   Recruiting — Phase 1 — Merck Sharp & Dohme LLC

   https://clinicaltrials.gov/study/NCT04938817

6. 6.

   Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

   Recruiting — Phase 3 — University College, London

   https://clinicaltrials.gov/study/NCT04685616

7. 7.

   FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

   Recruiting — Phase 1 — University of Birmingham

   https://clinicaltrials.gov/study/NCT04625907

8. 8.

   A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

   Recruiting — Phase 3 — Bristol-Myers Squibb

   https://clinicaltrials.gov/study/NCT06646276

9. 9.

   Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

   Recruiting — Phase 2 — Merck Sharp & Dohme LLC

   https://clinicaltrials.gov/study/NCT05587712

10. 10.

    A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

    Recruiting — Phase 1 — Race Oncology Ltd

    https://clinicaltrials.gov/study/NCT06815575

11. 11.

    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT06717347

12. 12.

    A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06283966

13. 13.

    A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

    Recruiting — Phase 3 — Celgene

    https://clinicaltrials.gov/study/NCT06911502

14. 14.

    Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06960577

15. 15.

    Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

    Recruiting — Phase 3 — University of Sydney

    https://clinicaltrials.gov/study/NCT02582697

16. 16.

    A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

    Recruiting — Phase 2 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT04684368

17. 17.

    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

    Recruiting — Phase 3 — BioNTech SE

    https://clinicaltrials.gov/study/NCT06712355

18. 18.

    A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

    Recruiting — Phase 2 — National Cancer Institute (NCI)

    https://clinicaltrials.gov/study/NCT05691478

19. 19.

    A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    Recruiting — Phase 2 — University of Birmingham

    https://clinicaltrials.gov/study/NCT05991388

20. 20.

    A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT07218029

21. 21.

    A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

    Recruiting — Na — McMaster University

    https://clinicaltrials.gov/study/NCT03127631

22. 22.

    Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

    Recruiting — Na — Weill Medical College of Cornell University

    https://clinicaltrials.gov/study/NCT04124120

23. 23.

    Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    Recruiting — Phase 3 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT03959085

24. 24.

    A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

    Recruiting — Phase 2 — Pfizer

    https://clinicaltrials.gov/study/NCT07073820

25. 25.

    A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

    Recruiting — Phase 1 — CStone Pharmaceuticals

    https://clinicaltrials.gov/study/NCT05279300

26. 26.

    IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    Recruiting — Phase 3 — Immunocore Ltd

    https://clinicaltrials.gov/study/NCT06112314

27. 27.

    A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

    Recruiting — Phase 3 — Regeneron Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06230224

28. 28.

    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT06966700

29. 29.

    A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

    Recruiting — Phase 2 — Tectonic Therapeutic

    https://clinicaltrials.gov/study/NCT06616974

30. 30.

    Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

    Recruiting — Phase 3 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT03067181

31. 31.

    Better Evidence and Translation for Calciphylaxis

    Recruiting — Phase 3 — University of Sydney

    https://clinicaltrials.gov/study/NCT05018221

32. 32.

    A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

    Recruiting — Phase 1 — CStone Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06741644

33. 33.

    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

    Recruiting — Phase 3 — National Cancer Institute (NCI)

    https://clinicaltrials.gov/study/NCT06172296

34. 34.

    A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

    Recruiting — Phase 3 — Amgen

    https://clinicaltrials.gov/study/NCT07005128

35. 35.

    A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    Recruiting — Phase 1 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06564038

36. 36.

    Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

    Recruiting — Phase 2 — The University of Queensland

    https://clinicaltrials.gov/study/NCT04310930

37. 37.

    Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

    Recruiting — Phase 3 — Martin Schrappe

    https://clinicaltrials.gov/study/NCT03643276

38. 38.

    High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

    Recruiting — Phase 3 — Gustave Roussy, Cancer Campus, Grand Paris

    https://clinicaltrials.gov/study/NCT04221035

39. 39.

    A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

    Recruiting — Phase 2 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT05504291

40. 40.

    A Personalised Approach Utilising the Frailty Index to Empower Consumers

    Recruiting — Na — Princess Alexandra Hospital, Brisbane, Australia

    https://clinicaltrials.gov/study/NCT05292989

41. 41.

    Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)

    Recruiting — Na — Baker Heart and Diabetes Institute

    https://clinicaltrials.gov/study/NCT04962711

42. 42.

    Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone

    Recruiting — Phase 4 — Murdoch Childrens Research Institute

    https://clinicaltrials.gov/study/NCT06186141

43. 43.

    Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

    Recruiting — Phase 2 — St. Anna Kinderkrebsforschung

    https://clinicaltrials.gov/study/NCT01949129

44. 44.

    Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

    Recruiting — Phase 3 — Merck Sharp & Dohme LLC

    https://clinicaltrials.gov/study/NCT03486873

45. 45.

    Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

    Recruiting — Phase 2 — Queensland Health

    https://clinicaltrials.gov/study/NCT05025813

46. 46.

    Extension Study for the Port Delivery System With Ranibizumab (Portal)

    Recruiting — Phase 3 — Hoffmann-La Roche

    https://clinicaltrials.gov/study/NCT03683251

47. 47.

    Pulmonary Hemodynamics During Exercise - Research Network

    Recruiting — Medical University of Graz

    https://clinicaltrials.gov/study/NCT03954574

48. 48.

    A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

    Recruiting — Phase 3 — Colorado Prevention Center

    https://clinicaltrials.gov/study/NCT06008197

49. 49.

    A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

    Recruiting — Phase 2 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT06368817

50. 50.

    A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

    Recruiting — Phase 3 — BioNTech SE

    https://clinicaltrials.gov/study/NCT06340568

51. 51.

    Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06357533

52. 52.

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

    Recruiting — Phase 3 — Genmab

    https://clinicaltrials.gov/study/NCT06191744

53. 53.

    Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06677060

54. 54.

    Novel Treatment of Radiation Associated Dysphagia With Statins

    Recruiting — Phase 2 — Peter MacCallum Cancer Centre, Australia

    https://clinicaltrials.gov/study/NCT07217938

55. 55.

    Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT07044336

56. 56.

    A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

    Recruiting — Phase 1 — Murdoch Childrens Research Institute

    https://clinicaltrials.gov/study/NCT06383338

57. 57.

    A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

    Recruiting — Phase 3 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT06401330

58. 58.

    Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

    Recruiting — Phase 1 — Celgene

    https://clinicaltrials.gov/study/NCT04884035

59. 59.

    A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

    Recruiting — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT07194070

60. 60.

    Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

    Recruiting — Phase 3 — Daiichi Sankyo

    https://clinicaltrials.gov/study/NCT06578247

61. 61.

    DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

    Recruiting — Phase 1 — DynamiCure Biotechnology

    https://clinicaltrials.gov/study/NCT05785754

62. 62.

    A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

    Recruiting — Phase 3 — Janssen Research & Development, LLC

    https://clinicaltrials.gov/study/NCT05912517

63. 63.

    A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

    Recruiting — Phase 1 — Hoffmann-La Roche

    https://clinicaltrials.gov/study/NCT05533775

64. 64.

    A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    Recruiting — Phase 3 — Regeneron Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06091254

65. 65.

    CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

    Recruiting — Phase 3 — Novo Nordisk A/S

    https://clinicaltrials.gov/study/NCT07207811

66. 66.

    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

    Recruiting — Phase 2 — Children's Oncology Group

    https://clinicaltrials.gov/study/NCT04322318

67. 67.

    High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

    Recruiting — Phase 3 — St. Anna Kinderkrebsforschung

    https://clinicaltrials.gov/study/NCT01704716

68. 68.

    International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

    Recruiting — Phase 3 — University of Birmingham

    https://clinicaltrials.gov/study/NCT02724163

69. 69.

    Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

    Recruiting — The University of Texas Health Science Center, Houston

    https://clinicaltrials.gov/study/NCT04005976

70. 70.

    Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

    Recruiting — Phase 2 — BioNTech SE

    https://clinicaltrials.gov/study/NCT06841055

71. 71.

    Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

    Recruiting — Phase 3 — Kite, A Gilead Company

    https://clinicaltrials.gov/study/NCT05605899

72. 72.

    EXtubation Related Complications - the EXTUBE Study (EXTUBE)

    Recruiting — University Health Network, Toronto

    https://clinicaltrials.gov/study/NCT06442930

73. 73.

    A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

    Recruiting — Phase 1 — Novartis Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06649110

74. 74.

    Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    Recruiting — Phase 3 — Gilead Sciences

    https://clinicaltrials.gov/study/NCT05633654

75. 75.

    A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    Recruiting — Phase 3 — National Cancer Institute (NCI)

    https://clinicaltrials.gov/study/NCT06124157